Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine and methacholine-induced bronchoconstriction in patients with asthma
- 34 Downloads
In a double blind, randomised, placebo controlled trial in a group of extrinsic asthmatics, we have evaluated the potency and selectivity of ebastine, a new piperidine-type H1-receptor antagonist, against histamine and methacholine-induced bronchoconstriction. The median histamine PC20FEV1 value following placebo was 3.15 mg/ml (0.24–58.84). When compared with placebo, ebastine produced significant protection at 10 mg (median PC20=31.36 mg/ml,p=0.008) and 30 mg (median PC20=42.14 mg/ml,p=0.001) but there appeared to be no significant dose effect. Ebastine also produced a small shift in the methacholine concentration-response curves to the right. We conclude that ebastine is an effective antagonist of histamine-induced bronchoconstriction in the asthmatic airway with evidence of minor blockade of methacholine-induced bronchoconstriction.
KeywordsPlacebo Asthma Histamine Placebo Control Trial Methacholine
Unable to display preview. Download preview PDF.
- J. Vincent, R. Liminana, P. A. Meredith and J. L. Reid,The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br. J. clin. Pharmac.26, 497–501 (1988).Google Scholar
- A. Taytard, D. Beaumont, J. C. Pujet, M. Sapene and P. J. Lewis,Treatment of bronchial asthma with terfenadine; a randomized controlled trial. Br. J. clin. Pharmac.24, 743–746 (1987).Google Scholar